Get the Stockscreener App
14.60
0.50%
0.0823
Janux Therapeutics Inc stock is traded at $14.60, with a volume of 65,858.
It is up +0.50% in the last 24 hours and down -2.78% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$14.52
Open:
$14.55
24h Volume:
65,858
Relative Volume:
0.07
Market Cap:
$890.98M
Revenue:
$10.00M
Net Income/Loss:
$-113.63M
P/E Ratio:
-7.9646
EPS:
-1.8334
Net Cash Flow:
$-83.28M
1W Performance:
+5.66%
1M Performance:
-2.78%
6M Performance:
-57.94%
1Y Performance:
-42.14%
1-Day Range:
$14.43
$14.67
1-Week Range:
$13.98
$14.87
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.61 | 885.49M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
436.02 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.02 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.99 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.34 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How (JANX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value - TipRanks
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12 - MSN
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus
Janux Therapeutics VP Maria Dobek sells $28,878 in stock By Investing.com - Investing.com Australia
Janux Therapeutics VP Maria Dobek sells $28,878 in stock - Investing.com India
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 - Stock Titan
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts - simplywall.st
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics - Stock Titan
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target - TipRanks
Lifesci Capital Comments on JANX Q2 Earnings - MarketBeat
LifeSci Capital Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics (JANX) Eps Diluted (TTM) - Zacks Investment Research
Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $58 - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.41, Implies 178% Upside - TradingView
RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating - marketscreener.com
Wedbush Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $58 - Moomoo
Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.94, Implies 182% Upside - TradingView
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14 - TipRanks
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
Janux Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BMS partnership boosts cash for Janux Therapeutics (NASDAQ: JANX) despite loss - Stock Titan
Janux Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Milestone payment and strong cash fuel Janux (NASDAQ: JANX) pipeline - Stock Titan
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q1 Revenue $3.7M, vs. FactSet Est of $4.4M - marketscreener.com
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - Yahoo Finance
FMR LLC files 13G/A on JANX (NASDAQ: JANX) for 2.54M shares - Stock Titan
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):